Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3100+0.0350 (+2.75%)
At close: 04:00PM EDT
1.3300 +0.02 (+1.53%)
After hours: 04:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2750
Open1.3000
Bid1.3000 x 900
Ask1.3100 x 4000
Day's Range1.2402 - 1.3100
52 Week Range0.9500 - 5.1800
Volume84,607
Avg. Volume72,293
Market Cap21.957M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Acquisition of global direct to consumer ecommerce business

    MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor

  • GlobeNewswire

    Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

    MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re

  • GlobeNewswire

    US Patent Office Grants Patent for COVID-19 Risk Test

    MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology incorporated into GENE’s geneType COVID-19 Risk Test, which provides a probability

Advertisement
Advertisement